Linezolid Fresenius Kabi (Linezolid)

Linezolid is an oxazolidinone antibacterial used to treat serious Gram‑positive infections.

• Complicated skin and soft tissue infections: effective against susceptible Gram‑positive bacteria, including MRSA, reducing infection severity.
• Community‑acquired and nosocomial pneumonia: provides bacteriostatic activity against the causative pathogens, improving respiratory outcomes.
• Infections caused by vancomycin‑resistant Enterococcus (VRE): offers an alternative treatment option for resistant Gram‑positive infections.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex. This blocks translation of essential proteins, resulting in a bacteriostatic effect against susceptible Gram‑positive organisms, including MRSA and VRE.

Linezolid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset occurring in many patients.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.
• Thrombocytopenia: reduction in platelet count, usually mild.

Serious or Rare Side Effects

• Myelosuppression: significant decrease in bone‑marrow activity leading to anemia or neutropenia.
• Peripheral neuropathy: nerve damage causing tingling or numbness, potentially irreversible.
• Lactic acidosis: accumulation of lactate causing metabolic acidosis, a life‑threatening condition.

When using Linezolid, clinicians should observe several safety considerations to minimize risks.

• Monitor blood counts: regular CBC testing to detect thrombocytopenia or anemia.
• Assess renal and hepatic function: adjust therapy if significant impairment is present.
• Watch for serotonin syndrome: avoid concomitant serotonergic agents.
• Evaluate for peripheral neuropathy: discontinue if symptoms develop.
• Use caution in pregnancy: limited data; risk‑benefit assessment required.
• Store at ambient temperature: keep below 25°C, protect from moisture and light in original packaging.

Linezolid can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic drugs: risk of serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): increased risk of hypertensive crisis.
• Rifampicin: reduces linezolid plasma concentrations, compromising effectiveness.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Ethanol: potential for disulfiram‑like reaction, causing flushing and nausea.
• Anticonvulsants (e.g., carbamazepine): may lower linezolid levels, necessitating therapeutic monitoring.